Table 1.
ACh content, ChAT and CarAT activities, and ChAT mRNA expression in human leukemic cell lines.
| Cell line | Cell type | ACh content pmol/106 cells | ChAT activity pmol/mg protein/min | CarAT activity pmol/mg protein/min | ChAT mRNA expression |
|---|---|---|---|---|---|
| CEM | T | 12.6 ± 0.6 | 2.9 ± 0.2 | 22.8 ± 4.6 | Positive |
| HSB-2 | T | 36.2 ± 3.5 | 1.4 ± 0.1 | 58.3 ± 15.3 | Positive |
| Jurkat | T | 8.2 ± 0.4 | 4.3 ± 0.8 | 17.2 ± 1.9 | Positive |
| MOLT-3 | T | 251.5 ± 34.9 | 22.4 ± 3.0 | 53.3 ± 5.6 | Positive |
| MOLT-4 | T | 38.8 ± 5.9 | 8.0 ± 1.0 | NT | Positive |
| BALL-1 | B | ND | 0.4 ± 02 | NT | Negative |
| Daudi | B | 1.2 ± 0.1 | 0.1 ± 0.02 | 125.6 ± 44.2 | Negative |
| NALM-6 | B | 0.04 ± 0.01 | 0.1 + 0.02 | NT | Negative |
| REH | Pre lymphoma | 0.8 ± 0.01 | 0.2 ± 0.03 | NT | Negative |
| U937 | Monocytic | 0.02 ± 0.01 | 0.2 ± 0.03 | NT | Negative |
Values are mean ± SEM.
ND, not detectable; NT, not tested.
ChAT activity was calculated from the difference in the ACh-synthesizing activities in the presence and absence of 100 µM bromoacetylcholine. CarAT activity was calculated from the difference in the Ach-synthesizing activities in the presence and absence of 100 μM bromoacetylcamitine. Data arranged from the studies by Fujii et al. (25) and Kawashima and Fujii (9).